



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Elizabeth A. Warren
United States Senate
Washington, D.C. 20510

Dear Senator Warren:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable John K. Fetterman
United States Senate
Washington, D.C. 20510

Dear Senator Fetterman:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Charles E. Schumer
United States Senate
Washington, D.C. 20510

Dear Senator Schumer:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Cory A. Booker
United States Senate
Washington, D.C. 20510

Dear Senator Booker:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Jeffrey A. Merkley
United States Senate
Washington, D.C. 20510

Dear Senator Merkley:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Bernard Sanders
United States Senate
Washington, D.C. 20510

Dear Senator Sanders:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Kirsten E. Gillibrand
United States Senate
Washington, D.C. 20510

Dear Senator Gillibrand:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Ron L. Wyden
United States Senate
Washington, D.C. 20510

Dear Senator Wyden:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable John W. Hickenlooper
United States Senate
Washington, D.C. 20510

Dear Senator Hickenlooper:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Peter F. Welch
United States Senate
Washington, D.C. 20510

Dear Senator Welch:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Chris Van Hollen
United States Senate
Washington, D.C. 20510

Dear Senator Van Hollen:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs



Department of Justice
Drug Enforcement Administration

Office of Congressional Affairs

Springfield, VA 22152

April 16, 2024

The Honorable Alex Padilla
United States Senate
Washington, D.C. 20510

Dear Senator Padilla:

Thank you for your January 29, 2024, letter regarding your interest in the scheduling of marijuana. We appreciate the opportunity to receive your concerns and questions.

For the Department of Justice (Department), and by delegation the Drug Enforcement Administration (DEA), to take an administrative scheduling action, it must follow the procedures that Congress set forth in the Controlled Substances Act, including an opportunity for a public comment period and a hearing. The Department of Justice is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.

On August 29, 2023, DEA received a letter from the Department of Health and Human Services (HHS) providing its findings and recommendation on marijuana scheduling, pursuant to President Biden's request for an administrative review. As part of this process, HHS first conducts a scientific and medical evaluation, and then DEA conducts its own review. DEA has the final authority under this administrative path to reschedule a drug under the Controlled Substances Act, after considering relevant statutory and regulatory criteria and HHS' scientific and medical evaluation.

We appreciate your ongoing interest in the Department's work.

Sincerely,

Michael D. Miller

Michael D. Miller
Acting Chief
Office of Congressional Affairs